CIK 0001857044 · Non-accelerated filer<br>Smaller reporting company
Indaptus Therapeutics, Inc.
Sign in to watch- Ticker
- INDP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 863158720
- Phone
- (646) 427-2727
- Business address
- 3 COLUMBUS CIRCLE, 15TH FLOOR, NEW YORK, NY, 10019
- Former names
- Intec Parent Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-09-08 | Meckler Jeffrey A CEO and Director | Purchase | +10,308 | $2.80 | $29K | 65,374 |
| 2022-09-07 | Linscott Walt Addison Chief Business Officer | Purchase | +150 | $2.62 | $393 | 150 |
| 2022-09-07 | Meckler Jeffrey A CEO and Director | Purchase | +8,632 | $2.57 | $22K | 55,066 |
| 2022-09-06 | Meckler Jeffrey A CEO and Director | Purchase | +1,060 | $2.44 | $3K | 46,434 |
| 2022-06-06 | Meckler Jeffrey A CEO and Director | Purchase | +19,727 | $2.63 | $52K | 45,374 |
| 2022-03-02 | Litchev Boyan Vesselinov Chief Medical Officer | Purchase | +50 | $4.09 | $205 | 150 |
| 2022-02-25 | Sassi Nir Chief Financial Officer | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2022-02-01 | Litchev Boyan Vesselinov Chief Medical Officer | Grant or award · Stock Option (right to buy) | +90,000 | 90,000 | ||
| 2022-02-01 | Newman Michael James CSO and Director | Sale | −14,130 | $5.00 | $71K | 1,368,356 |
| 2022-01-31 | Litchev Boyan Vesselinov Chief Medical Officer | Purchase | +100 | $4.65 | $465 | 100 |
| 2022-01-31 | Newman Michael James CSO and Director | Sale | −5,870 | $5.00 | $29K | 1,382,486 |
| 2022-01-26 | Newman Michael James CSO and Director | Grant or award · Stock Option (right to buy) | +43,350 | 43,350 | ||
| 2022-01-26 | Meckler Jeffrey A CEO and Director | Grant or award · Stock Option (right to buy) | +200,000 | 200,000 | ||
| 2022-01-26 | Linscott Walt Addison Chief Business Officer | Grant or award · Stock Option (right to buy) | +45,850 | 45,850 | ||
| 2021-12-01 | Gilbert Mark John Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2021-11-18 | Meckler Jeffrey A CEO and Director | Purchase | +11,187 | $5.82 | $65K | 25,647 |
| 2021-09-14 | Meckler Jeffrey A CEO and Director | Purchase | +12,000 | $7.00 | $84K | 14,460 |
| 2021-08-04 | Linscott Walt Addison Chief Business Officer | Grant or award · Stock Option (right to buy) | +210,000 | 210,000 | ||
| 2021-08-04 | Meckler Jeffrey A CEO and Director | Grant or award · Stock Option (right to buy) | +375,000 | 375,000 | ||
| 2021-08-04 | Pomerantz Roger Director | Grant or award · Stock Option (right to buy) | +41,000 | 41,000 |
Page 6 of 7 · 127 trades